Bristol-Myers Squibb and Pfizer report data from real-world analysis of Eliquis

Bristol-Myers Squibb and Pfizer have announced the findings of a real-world analysis that further underlines the benefits offered by their anticoagulant Eliquis.

The analysis used data from the Humana database, which includes managed care medical and pharmacy claims from more than 20 million persons primarily residing in the southern and midwestern regions of the US.

It was shown that treatment with Eliquis was associated with a significantly lower risk of stroke/systemic embolism and lower rates of major bleeding compared to warfarin in patients aged 65 years and older with non-valvular atrial fibrillation.

This comes as part of the broader global real-world data analysis programme ACROPOLIS, which is assessing the performance of Eliquis through the study of de-identified medical records, medical and pharmacy health insurance claims data, and national health data systems.

Dr Rory O'Connor, chief medical officer at Pfizer Innovative Health, said: "Through these real-world analyses, we continue to add to the growing body of evidence around the effects of Eliquis in commonly seen patient groups such as the elderly."

The drug was developed by Pfizer and Bristol-Myers Squibb as a means of reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the prophylaxis of deep vein thrombosis.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.